Aequus Reports Q2 2017 Financials

Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) released their operational financial results for the second quarter of 2017.
As quoted in the press release:

Commercial Activities
The Company recorded revenues of $186,586 in the three month period ending June 30, 2017, representing 58% of growth as compared to the same period in 2016. On a year-to-date basis, the Company recorded $479,588 in revenues in the six month period ending June 30, 2017, a 105% growth compared to the same period in 2016. Revenues were attributable to its promotional activities for its third party products, Tacrolimus IR and ^PRVistitan™.
Since the initiation of Aequus’ promotional efforts in December 2015, the generic version of the most commonly used dose of tacrolimus IR (1mg) has experienced growth of 103% to date and continues to gain market share from branded tacrolimus alternatives. Since the launch of Vistitan™ in April 2016, and with the support of Aequus’ promotional efforts, Vistitan™ has been successfully listed among 90% of private payor groups as well as a benefit under key provincial formularies, including the Ontario Drug Benefit Plan, Alberta Health and Manitoba Health.

Click here to read the full press release.

Source: www.marketwired.com